11 Biotechnology Stocks to Buy Now

The grades of 11 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Genomic Health, Inc. (GHDX) shows solid improvement this week. The company’s rating rises from a C to a B. Genomic Health, Inc. is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

This is a strong week for Sarepta Therapeutics, Inc. (SRPT). The company’s rating climbs to B from the previous week’s C. Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of unique RNA-based therapeutics for the treatment of both rare and infectious diseases. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of SRPT stock.

Grifols, S.A. Sponsored ADR Class B (GRFS) gets a higher grade this week, advancing from a C last week to a B. Grifols, S.A. Sponsored ADR Class B develops, manufactures, and markets plasma derivatives, IV Therapy, Enteral nutrition, diagnostic systems, and medical materials. For more information, get Portfolio Grader’s complete analysis of GRFS stock.

Lexicon Pharmaceuticals, Inc. (LXRX) is seeing ratings go up from a B last week to a A this week. Lexicon Pharmaceuticals, Inc. researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of LXRX stock.

Minerva Neurosciences Inc’s (NERV) ratings are looking better this week, moving up to a B from last week’s C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of NERV stock.

This week, Vitae Pharmaceuticals, Inc.’s (VTAE) ratings are up from a C last week to a B. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VTAE stock.

MediciNova, Inc. (MNOV) improves from a B to a A rating this week. MediciNova, Inc. acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

Sinovac Biotech Ltd. (SVA) boosts its rating from a C to a B this week. Sinovac Biotech Ltd. researches, develops, manufactures, and markets various vaccines, including flu vaccines and vaccines for Hepatitis A. For more information, get Portfolio Grader’s complete analysis of SVA stock.

This week, Arrowhead Pharmaceuticals, Inc. (ARWR) pushes up from a C to a B rating. Arrowhead Pharmaceuticals, Inc. a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. The company also gets A’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARWR stock.

The rating of Corbus Pharmaceuticals Holdings Inc (CRBP) moves up this week, rising from a C to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CRBP stock.

Biostage, Inc. (BSTG) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of BSTG stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/06/11-biotechnology-stocks-to-buy-now-2/.

©2021 InvestorPlace Media, LLC